Kolon Life Science Inc.

KOSDAQ:A102940 Stock Report

Market Cap: ₩291.3b

Kolon Life Science Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Sun Jin Kim

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.7yrs
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

There's Reason For Concern Over Kolon Life Science Inc.'s (KOSDAQ:102940) Massive 45% Price Jump

Dec 13
There's Reason For Concern Over Kolon Life Science Inc.'s (KOSDAQ:102940) Massive 45% Price Jump

Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%

We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt

Mar 12
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt

A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns

Jan 18
A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns

Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt

Nov 26
Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt

CEO

Sun Jin Kim (63 yo)

1.7yrs

Tenure

Mr. Sun Jin Kim, M.D, Ph D, is Chief Executive Officer at Kolon Life Science Inc. since April 2023 and serves as its Director. He has been the Chief Medical Officer at Kolon TissueGene, Inc. since June 202...


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:32
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kolon Life Science Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JooYong KimBookook Securities Co. Ltd
Bora ChungDaishin Securities Co. Ltd.
Ha Young KangDAOL Investment & Securities Co., Ltd.